FAM20B Protein, Human (HEK293, Fc)

The FAM20B protein plays a key role in regulating mature glycosaminoglycan (GAG) chains by catalyzing xylose 2-O-phosphorylation in the glycosaminoglycan-protein linking region of the proteoglycan. This process is critical for the synthesis of sulfated GAGs (such as heparan sulfate and chondroitin sulfate) on the common GAG-protein linking region (GlcUAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1-O-Ser) of the core protein. FAM20B Protein, Human (HEK293, Fc) is the recombinant human-derived FAM20B protein, expressed by HEK293 , with N-hFc labeled tag. The total length of FAM20B Protein, Human (HEK293, Fc) is 379 a.a., with molecular weight of ~75-80 KDa.

The FAM20B protein assumes a pivotal role in the regulation of mature glycosaminoglycan (GAG) chains by catalyzing the 2-O-phosphorylation of xylose within the glycosaminoglycan-protein linkage region of proteoglycans. This process is integral to the synthesis of sulfated GAGs, including heparan sulfate and chondroitin sulfate, on the common GAG-protein linkage region (GlcUAbeta1-3Galbeta1-3Galbeta1-4Xylbeta1-O-Ser) of core proteins. The stepwise addition of monosaccharide residues by specific glycosyltransferases forms this linkage region, where xylose 2-O-phosphorylation plays a regulatory role in the catalytic activity of B3GAT3 (GlcAT-I). B3GAT3 completes the precursor tetrasaccharide of GAG-protein linkage regions, serving as a foundation for the subsequent synthesis of the repeating disaccharide region. FAM20B's involvement in xylose 2-O-phosphorylation highlights its crucial contribution to the precise regulation of GAG chain assembly and the intricate orchestration of glycosaminoglycan structures.

Measured by its ability to enhance survival of ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is 1.464 μg/mL. Corresponding to a specific activity is 683.06 unit/mg.

• 
  Measured by its ability to enhance survival of ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is 1.464 μg/mL. Corresponding to a specific activity is 683.06 Unit/mg.

Human

HEK293

N-hFc

O75063/NP_055679.1 (S31-L409)

9917  [NCBI]

SAANREDQRAFHRMMTGLRVELAPKLDHTLQSPWEIAAQWVVPREVYPEETPELGAVMHAMATKKIIKADVGYKGTQLKALLILEGGQKVVFKPKRYSRDHVVEGEPYAGYDRHNAEVAAFHLDRILGFHRAPLVVGRFVNLRTEIKPVATEQLLSTFLTVGNNTCFYGKCYYCRETEPACADGDIMEGSVTLWLPDVWPLQKHRHPWGRTYREGKLARWEYDESYCDAVKKTSPYDSGPRLLDIIDTAVFDYLIGNADRHHYESFQDDEGASMLILLDNAKSFGNPSLDERSILAPLYQCCIIRVSTWNRLNYLKNGVLKSALKSAMAHDPISPVLSDPHLDAVDQRLLSVLATVKQCTDQFGMDTVLVEDRMPLSHL

Approximately 75-80 kDa due to the glycosylation

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.